PMC6875264_01
Overview of the therapeutic regimens and tumor marker fluctuations in patient case 1, who used up to nine different targeted drugs over a 2 years period. The arrows under the line chart indicate the therapeutic regimen for each time (dash arrow means period of targeted therapy pause). The central curves indicate fluctuations of tumor markers.
OTT-12-9941-g0001.jpg
PMC6875264_01_OTT-12-9941-g0001.jpg
F0001
The patient refused chemotherapy and then administered the mixed cocktail targeted therapy by himself, with nine molecular-specific agents (Figure 1).
PMC6875264_02
Radiological evidence for the shrank target lesions from the patient in case 2, who received alternative cabozantinib and axitinib for 3 months ((A) prior the treatment; (B) post treatment).
OTT-12-9941-g0002.jpg
PMC6875264_02_OTT-12-9941-g0002.jpg
F0002
The 3-month post-therapy assessment suggested overall SD with shrinkage of lesions (Figure 2A and B), while at 6.5-month post-therapy, our evaluation confirmed cancer progression with emerging metastases and increase in size of the primary lesions.